Jakarta, Friday 22 May 2025: Dharmais Cancer Hospital, National Cancer Center Indonesia (Dharmais) and Bionyeri Pty Ltd (Bionyeri) have today signed a Memorandum of Understanding (MOU) for a five-year project to implement new techniques for identifying and treating cancer.
Bionyeri will work with Dharmais to develop new Artificial Intelligence applications which will accelerate cancer prognosis and diagnosis by as much as 60 per cent. This will significantly assist clinicians to identify cancer types more rapidly and to apply personalised treatment for cancer patients.
The project will also include the development of new natural anti-cancer adjuvants along with natural products for pain and for skin damage resulting from radiotherapy.
Initially the project will focus on patients with triple negative breast cancer which is the most prevalent cancer type in Indonesia. It will then expand to the other most dominant cancers of cervical, lung and colorectal.
Speaking at the official signing ceremony today, and Dr R. Soeko W. Nindito, President Director of Dharmais Cancer Hospital, National Cancer Center Indonesia said: “This collaboration between RS Dharmais and Bionyeri is expected to become a unified force to deliver effective and meaningful benefits for cancer patients across Indonesia.”
Mr Eng Liang Tan, Bionyeri Co-Founder and Chairman and President Commissioner of PT Soho Global Health added: “I hope that moving forward, we can fully harness the potential of Indonesia’s herbal plants for the health, social and economic benefits of our nation and its people.”
Dr Evlina Suzanna, MD. Path. from Dharmais Cancer Hospital and Professor Gilles Guillemin, CEO of Bionyeri will lead the project team which are from both Indonesia and Australia.
Mr Tan and Dr R. Soeko were signatories for the MOU.
Bionyeri and Dharmais are grateful for the support from the Ministry of Health of the Republic of Indonesia for this important project that will help improve the cancer care and quality of life of millions of cancer sufferers in Indonesia.
[ends]
About Bionyeri Pty Ltd: www.bionyeri.com
Bionyeri is a Research and Development Biotech company based in Sydney Australia.Our focus is on using bioactive and plant extracts to develop a new generation of natural products with enhanced delivery techniques to help relieve symptoms of pain in a range of health conditions.
Our vision is to become a market leader in the development of natural products for pain and cancer relief which are backed by scientific evidence and experiments conducted from our PC2 accredited facility.
About Kemenkes RSK Dharmais: https://dharmais.co.id
As a National Cancer Center, Dharmais Cancer Hospital continues to develop itself to provide quality services to the community. Dharmais Cancer Hospital began with the aspiration to establish integrated cancer services in Indonesia by cancer experts. The opportunity opened in 1988 when the chairman of the Dharmais foundation Mr. H. M. Soeharto asked Prof. Dr. dr. Arry. Harryanto Reksodiputro, Sp.PD.KHOM, to think of a cancer hospital model that suits the needs of the Indonesian people. Established in 1993, Dharmais Cancer Hospital delivers cancer services in Indonesia and has commitment for best practices in oncology.
